Financial analysis of chronic transfusion for stroke prevention in sickle cell disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Chronic red blood cell transfusion can prevent many of the manifestations of sickle cell disease. The medical costs of chronic transfusion and management of associated side effects, especially iron overload, are considerable. This study was undertaken to evaluate the financial impact of chronic transfusion for stroke prevention in patients with sickle cell anemia. Outpatient charges pertaining to hospital-based Medicare uniform bill (UB-92) codes, professional fees, and iron chelation were evaluated. Data were collected on 21 patients for a total of 296 patient months (mean, 14; median, 14 months/patient). Charges ranged from $9828 to $50 852 per patient per year. UB-92, chelation, and physician-related charges accounted for 53%, 42%, and 5% of total charges, respectively. Of UB-92 charges, 58% were associated with laboratory fees and 16% were related to the processing and administration of blood. Charges for patients who required chelation therapy ranged from $31 143 to $50 852 per patient per year (mean, $39 779; median, $38 607). Deferoxamine accounted for 71% of chelation-related charges, which ranged from $12 719 to $24 845 per patient per year (mean, $20 514; median, $21 381). The financial impact of chronic transfusion therapy for sickle cell disease is substantial with charges approaching $400 000 per patient decade for patients who require deferoxamine chelation. These data should be considered in reference to cost and efficacy analyses of alternative therapies for sickle cell disease, such as allogeneic bone marrow transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Adams, R. J., McKie, V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390102 · Cited by 1,866 · cited 1×
“UB-92-391 (transfusion) 56 311 (16)† 8 213 (7)† 48 098 (19)†”
Self-citationCerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
Self-citationThe natural history of stroke in sickle cell disease
Powars, D., Wilson, B., Imbus, C., Pegelow, C., & Allen, J. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90772-6 · Cited by 594 · cited 1×
“UB-92-391 (transfusion) 56 311 (16)† 8 213 (7)† 48 098 (19)†”
Self-citationStroke in a cohort of patients with homozygous sickle cell disease
Balkaran, B., Char, G., Morris, J. S., Thomas, P. W., Serjeant, B. E., & Serjeant, G. R. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80897-2 · Cited by 419
Cited by
Activity‐based costs of blood transfusions in surgical patients at four hospitals
Shander, A., Hofmann, A., Ozawa, S., Theusinger, O. M., Gombotz, H., & Spahn, D. R. (2010) · Transfusion · doi:10.1111/j.1537-2995.2009.02518.x · Cited by 747
The cost of health care for children and adults with sickle cell disease
Kauf, T. L., Coates, T. D., Huazhi, L., Mody‐Patel, N., & Hartzema, A. G. (2009) · American Journal of Hematology · doi:10.1002/ajh.21408 · Cited by 388
Bernaudin, F., Verlhac, S., Arnaud, C., Kamdem, A., Chevret, S., Hau, I., Coïc, L., Leveillé, E., Lemarchand, E., Lesprit, E., et al. (2011) · Blood · doi:10.1182/blood-2010-06-293514 · Cited by 336
Sickle cell disease: time for a closer look at treatment options?
Sheth, S., Licursi, M., & Bhatia, M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12413 · Cited by 57
“Vascular access, availability of and compliance with iron chelation and the high cost ($40 000/year in 2000; Wayne et al, 2000) are some of the other reasons why regular transfusion is not an optimal option for universal therapy.”
BackgroundBelisário, A. R., Sales, R. R., Toledo, N. E., Muniz, M. B. D. S. R., Velloso-Rodrigues, C., Silva, C. M., & Viana, M. B. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2789-5 · Cited by 29
Metadata
- Authors
- Wayne, A. S., Schoenike, S. E., & Pegelow, C. H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-10-01
- Volume
- 96
- Issue
- 7
- Pages
- 2369-2372
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2137879252
- Cited by
- 71
- References
- 5
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. https://app.cochat.ai/papers/10.1182/blood.v96.7.2369
- The paper
- Wayne, A. S., Schoenike, S. E., & Pegelow, C. H. (2000). Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood. https://doi.org/10.1182/blood.v96.7.2369
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.